StockNews.com assumed coverage on shares of Veradigm (NASDAQ:MDRX – Free Report) in a report issued on Sunday. The firm issued a hold rating on the software maker’s stock.
Separately, TD Cowen dropped their price target on shares of Veradigm from $26.00 to $15.00 and set a buy rating on the stock in a research note on Tuesday, May 28th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, Veradigm presently has a consensus rating of Hold and an average price target of $12.00.
Get Our Latest Stock Report on Veradigm
Veradigm Stock Down 0.9 %
Institutional Investors Weigh In On Veradigm
A number of institutional investors and hedge funds have recently made changes to their positions in MDRX. Innealta Capital LLC acquired a new position in Veradigm during the 2nd quarter worth approximately $38,000. TFO Wealth Partners LLC raised its position in Veradigm by 105,280.0% during the fourth quarter. TFO Wealth Partners LLC now owns 5,269 shares of the software maker’s stock worth $52,000 after acquiring an additional 5,264 shares during the last quarter. Meadow Creek Wealth Advisors LLC purchased a new stake in Veradigm in the 1st quarter valued at approximately $83,000. Forest Hill Capital LLC purchased a new stake in Veradigm during the 4th quarter worth about $210,000. Finally, Aigen Investment Management LP purchased a new stake in shares of Veradigm during the fourth quarter worth about $231,000.
Veradigm Company Profile
Veradigm Inc, a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions.
Read More
- Five stocks we like better than Veradigm
- The Basics of Support and Resistance
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- The Role Economic Reports Play in a Successful Investment Strategy
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- What Are Growth Stocks and Investing in Them
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Veradigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veradigm and related companies with MarketBeat.com's FREE daily email newsletter.